Inflation Reduction Act Likely to Have a Negative Financial Impact On Many Drug ManufacturersOn August 16, 2022, the Inflation Reduction Act of 2022 was signed into law with provisions aimed at lowering drug, health care and energy costs for consumers in the United...
Branded Prescription Drug Fee – Payment Deadline ApproachingFriendly reminder to all of our industry colleagues! The final Branded Prescription Drug Fee invoices should be mailed soon. No later than August 31st of each year, the IRS mails the final fee calculation to...
Part I – Unwinding Medicaid Continuous Enrollment May 2022After a slight decline from 2017 to 2019, Medicaid enrollment rose sharply throughout the pandemic. Historically, Medicaid enrollment tracks with unemployment rates. When rates rise, enrollment increases....
Reasons to prepare now for the 2024 Medicaid rebate cap removalDoes it feel like proposed Medicaid rule changes are too far in the future to think about? Or the proposed changes appear so dramatic that it seems unlikely to pass into law, so there’s little need to...
2023 Final Rule Updates for Drug Manufacturers Originally published March 2022; updated May 2022UPDATE May 18, 2022 2023 was shaping up to be a year of challenging decisions for manufacturers and restricted access to critical pharmaceuticals for patients. The 2023...
American Rescue Plan Act of 2021: Medicaid Rebate Inflation Penalties Will Soon Know No BoundsOn March 11, 2021, President Joe Biden signed into law the American Rescue Plan Act of 2021 (ARP21), also known as the COVID-19 Relief Bill. Many pharmaceutical manufacturers...
Another Update on Drug Price Disclosure LegislationMore tips for staying compliant with an accelerating trendStates Continue Their March Toward Prescription Drug Transparency Regulations. This paper, our fourth in a series that looks at the rising number of price...
Continued Emergence of Drug Price Disclosure Legislation Tips for staying compliant with an accelerating trend The summer of 2019 saw an 86 percent increase in the number of states enacting pharmaceutical drug price disclosure laws. This paper, our second in a series...